Our findings suggest that, despite the increased expression of some of these markers, including CD133, CD166, and CD44s, from normal to early colorectal cancer, it is the overall decreased membranous expression, particularly of EpCAM, CD166, and CD44s, which is linked to a more aggressive tumour phenotype. This evidence concerns the gene ALCAM and colorectal cancer.